An observational study in Benign Prostatic Hypertrophy (BPH) and Lower Urinary Track Symptoms, sponsored by Benaroya Research Institute. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Benaroya Research Institute · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 29th largest by planned enrollment of the 37 observational ones that give a count, is one of 15 that started in 2026, is one of 37 observational ones, reaches primary completion later than 21 of the 47 other live ones, and was the 170th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 250 across 178 observational studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 201 across the 37 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 188 have an industry lead sponsor. The 10 most frequent:
Benaroya Research Institute is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
Benaroya Research Institute has 1 study filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are amongst the gold standard surgical treatments for BPH. However, in the immediate post-operative period, TURP and Aquablation can also include OAB-like symptoms, including urinary frequency and urgency. For men with baseline OAB symptoms, this initial worsening of symptoms can be distressing.
Botox is an FDA approved medication with on-label indications to treat overactive bladder.
The purpose of this study is to evaluate the outcomes of men who have Botox concurrent with their TURP or Aquablation.
The study population will be identified by patients visiting the Virginia Mason Medical Centers Urology department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will contain men (\>=18 years) and will be scheduled to undergo TURP or Aquablation and Botox procedure.
Other: Survey using a questionnaire.
* 1 week post-operative visit for: trial of void, to assess for rates of postoperative urinary retention. * 4 and 12 week post-operative visits for: post void residual assessment via bladder scan, AUA symptom score, PGI-I, UDI-6, and VM Post Procedure questionnaires will be administered * Hospitalization readmission rates, urinary retention episodes will also be recorded.
Also known as: AUA symptom score, PGI-I, UDI-6, VM Post Procedure questionnaires, post void residual assessment via bladder scan
To identify whether concurrent Botox and TURP or Aquablation are effective at reducing post-operative irritative voiding symptoms.
This will be measured using Postoperative Urinary Retention (POUR): At 1 week post-operative visit for trial of void to assess for rates of postoperative urinary retention. At 4 and 12 week post-operative visits for post void residual assessment
Time frame: 4 months
To identify whether concurrent Botox and TURP or Aquablation lead to longer hospitalizations.
Analyzing admission data to determine if there are any changes to the hospital admission rates.
Time frame: 4 months
To identify whether concurrent Botox and TURP or Aquablation lead to higher rates of urinary retention.
Analyzing admission data to determine if there are any changes to the urinary retention episodes.
Time frame: 4 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Virginia Mason Urology providers will identify patients for potential study participation. Informed consent will be obtained for all subjects who wish to participate in this trial. Upon consent, study staff will obtain baseline and demographic data, administer AUA symptom score and the UDI-6. At follow up visits, the AUA symptom score, UDI-6, PGI-I, and VM post-procedure questionnaire will be obtained for participating patients. Additional data points under study will be obtained from the subject's electronic medical record. All study data will be entered into a secure password-protected clinical research database maintained on a Virginia Mason computer. No PHI will be transferred outside of Virginia Mason.
Start is estimated for Jan 2026; primary completion for May 2027, 15 months later.
Of 60 non-industry observational studies under Prostatic Hyperplasia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 15 months is below that.
Counting every sponsor, half of 76 studies reached it within 25 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Benaroya Research Institute